Dr. Shafik Sachedina is Sussex healthcare’s joint chairman, a position that he has been holding for the last 20 years since 1998. Highly respected in the UK society as a premium entrepreneur and healthcare specialist Dr. Shafik Sachedina traces his history back in Tanzania in East Africa where he was born in 1950. Trained as a surgeon from the University of London, Dr. Sachedina has a tremendous level of experience and expertise, both at the doctoral level as well as the entrepreneurial level. Find out more about Shafik Sachedina at Behance.
According to his biography, after completing his education at the University of London, Dr. Shafik Sachedina worked as a volunteer at Aga Khan where he helped serve the society through various philanthropic programs on a volunteer basis. His prowess and experience in management of healthcare institutions saw him appointed as the chairman of Sussex Healthcare. He has helped transform the Sussex Healthcare to become one of the premium-quality healthcare service centers that are known for its home-based care services particularly for the aged persons in the society.
Dr. Shafik Sachedina has also helped in the transformation of Sussex Healthcare into one of the leading healthcare service providers operating within the UK market, especially in western Sussex. He has also overseen the rollout of numerous healthcare programs that have been instrumental towards serving members of the public suffering from age-related conditions such as Alzheimer’s disease, dementia, and other neurological conditions that are prominent among elderly persons.
Among other changes and developments that Dr. Shafik Sachedina has helped bring about in Sussex healthcare include the emphasis on patient service while focusing on the development of the healthcare institutions’ workers professionalism by sponsoring them to undertake diploma-level of education in professional practice. This program has helped most workers find passion in working at Sussex healthcare through the advancement of their skills and knowledge base, thereby increasing the retention levels of professional workers and nurses. Dr. Sachedina has also been instrumental in the transformation of Sussex healthcare service provision model to ensure that patients are accorded the highest quality of medical service whereby their recovery is expedited through the provision of an ambient environment that offers social and therapeutic comfort.
Amicus Therapeutics is an American biopharmaceutical company based in New Jersey. It became a public company in 2007 and was funded by a variety venture capital companies including Enterprise Associates, Canaan Partners and Radius Ventures.
Main Focus of Amicus Therapeutics
The company mainly focuses on rare and orphan diseases. They offer medicine and unique technologies in the development of patients suffering from devastating and rare diseases such as the lysosomal storage disorder, Fabry disease, epidermolysis bullosa (EB); a genetic connective skin disorder, and Pompe diseases. The company’s lead upcoming product is Migalastat, a personalized drug that is in late-stage development to treat people with Fabry disease based on person’s genetic diagnosis.
Another candidate in the late stage development is SD-101, a possible first-to- market therapy for epidermolysis bullosa (EB). The company is also trying to advance its biologics and the Chaperone-Advanced Replacement Therapy, a platform advancement to invent Novel Enzyme Replacement Therapy products, for Pompe disease, Fabry diseases, and other various lysosomal storage disorders. The therapeutics frontline program is ATB200/AT2221, a uniquely Pompe disease enzyme replacement therapy, which is administered together with a pharmacological chaperone.
The Developmental Journey of Amicus Therapeutics
Amicus Therapeutics did not have a manufacturing capability and only relied on contract manufacturing alone. Luckily, the company expanded from New Jersey to another site in San Diego in 2008. Amicus then acquired competitor Callidus Biopharma, hence obtaining essential materials and advanced property for the Enzyme Replacement Therapy treatment of pompe disease. As of February 2014, Amicus Therapeutics still had no marketed products. Its most advanced potential product was migalastat (ReleaseFact). Between 2010 and 2013 the company collaborated with JCR Pharmaceutical and GlaxoSmithKline to research on formulation with recombinant alpha-galactosidase. Later in 2015 September, Amicus acquired Scioderm for around 947 million dollars in cash and stock.
Amicus Activities outside America
The company is committed to the Fabry community across the world and has recently seen approval of its migalastat by Health Canada for treatment of Fabry diseases in the country (https://www.google.com/finance?cid=706165). Amicus Therapeutics also attended and sponsored the Thirteenth International Congress of inborn metabolism errors, in Rio de Janeiro Brazil, to adopt the research of genetically passed metabolic disorders and related topics. The company’s CEO John Crowley was nominated in the 2017 PharmaVoicelist for his ground-breaking development of rare disease drugs.